INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 54 filers reported holding INOZYME PHARMA INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $410,029 | +32.6% | 97,626 | +75.9% | 0.00% | – |
| Q2 2023 | $309,152 | +367.2% | 55,503 | +380.6% | 0.00% | – |
| Q1 2023 | $66,170 | +787.0% | 11,548 | +62.5% | 0.00% | – |
| Q4 2022 | $7,460 | -6.8% | 7,105 | +142.7% | 0.00% | – |
| Q3 2022 | $8,000 | – | 2,927 | +41714.3% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 7 | -99.9% | 0.00% | – |
| Q1 2022 | $28,000 | -65.4% | 6,647 | -43.9% | 0.00% | – |
| Q4 2021 | $81,000 | +1925.0% | 11,853 | +4030.0% | 0.00% | – |
| Q3 2021 | $4,000 | -90.7% | 287 | -88.5% | 0.00% | – |
| Q2 2021 | $43,000 | -81.4% | 2,504 | -78.5% | 0.00% | – |
| Q1 2021 | $231,000 | +5675.0% | 11,658 | +6412.8% | 0.00% | – |
| Q4 2020 | $4,000 | -66.7% | 179 | -63.2% | 0.00% | – |
| Q3 2020 | $12,000 | – | 487 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |